复方瑞格列克长期治疗症状性子宫平滑肌瘤
LIBERTY 1和LIBERTY 2安慰剂对照试验的28周长期扩展研究纳入477名完成原试验的子宫平滑肌瘤相关月经过多女性,所有参与者每日一次接受复方瑞格列克(瑞格列克40 mg、雌二醇1 mg、醋酸炔诺酮0.5 mg)治疗至52周。复方瑞格列克治疗52周时,87.7%的患者维持或达到月经过多改善,月经失血量最小二乘均值降低89.9%,70.6%达到闭经,骨密度维持至52周,未发现新的安全性问题。
要点
- 复方瑞格列克治疗52周时87.7%患者月经过多持续改善(应答者)。
- 月经失血量最小二乘均值降低89.9%,70.6%患者达到闭经。
- 基线贫血患者中59.0%在52周时血红蛋白浓度改善大于2 g/dL。
核心结论
- 复方瑞格列克治疗至52周可持续改善子宫平滑肌瘤女性的月经过多和贫血,并减轻肌瘤相关症状负担。
- 未发现新的安全性问题,骨密度得以维持。
研究设计与样本
- LIBERTY 1和LIBERTY 2安慰剂对照试验的28周长期扩展研究。
- 完成LIBERTY 1或LIBERTY 2任一组治疗的子宫平滑肌瘤相关月经过多女性入组扩展研究。
- 扩展研究中所有参与者每日一次接受复方瑞格列克(瑞格列克40 mg、雌二醇1 mg、醋酸炔诺酮0.5 mg)。
- 共477名女性入组,476名接受治疗,363名(76.1%)完成52周。
- 主要疗效终点为从LIBERTY研究基线至治疗最后35天月经失血量小于80 mL且较基线降低50%或以上的女性比例(应答者)。
主要发现
- 接受复方瑞格列克治疗至52周的患者(n=163)中,87.7%为应答者。
- 月经失血量最小二乘均值降低89.9%,70.6%的患者达到闭经。
- 第52周时,基线贫血患者中59.0%血红蛋白浓度改善大于2 g/dL。
- BPD(出血与盆腔不适)量表评分的肌瘤相关症状困扰降低51.3分。
- 子宫和子宫平滑肌瘤体积持续缩小,骨密度维持至第52周。
关键数值与推荐
- 应答者定义为月经失血量小于80 mL且较LIBERTY研究基线降低50%或以上。
- 复方瑞格列克剂量为瑞格列克40 mg、雌二醇1 mg、醋酸炔诺酮0.5 mg,每日一次。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In the LIBERTY 1 and LIBERTY 2 placebo-controlled trials, once-daily relugolix combination therapy reduced menstrual blood loss volume and pain in women with heavy menstrual bleeding associated with uterine leiomyomas and was well tolerated, with preservation of bone mineral density (BMD) through 24 weeks. Here we report the long-term efficacy and safety of relugolix combination therapy treatment for up to 52 weeks. METHODS: Women with uterine leiomyoma-associated heavy menstrual bleeding who completed any treatment arm in either the LIBERTY 1 or LIBERTY 2 trial were eligible to enroll in a 28-week long-term extension study. All participants received once-daily relugolix combination therapy (40 mg relugolix, estradiol 1 mg, norethindrone acetate 0.5 mg) in the extension study. The primary efficacy endpoint was the proportion of women who achieved or maintained a menstrual blood loss volume of less than 80 mL and a 50% or greater reduction in menstrual blood loss volume from LIBERTY study baseline to the last 35 days of treatment (defined as responders ). Analyses were conducted for all three randomized treatment groups from pivotal studies. RESULTS: Overall, 477 women enrolled, 476 were treated, and 363 (76.1%) completed 52 weeks. Among patients treated with relugolix combination therapy through 52 weeks (n=163), sustained improvement in heavy menstrual bleeding was observed in 87.7% (responders). The least squares mean menstrual blood loss volume reduction was 89.9%, with 70.6% of patients achieving amenorrhea. At week 52, 59.0% of patients with anemia at baseline had improvements in hemoglobin concentration of greater than 2 g/dL. Distress due to uterine leiomyoma-associated symptoms measured by the BPD (Bleeding and Pelvic Discomfort) scale score was reduced by 51.3 points. Sustained reductions in uterine and uterine leiomyoma volume were observed. Bone mineral density was preserved through week 52. CONCLUSION: Improvements in heavy menstrual bleeding and anemia and reduction of uterine leiomyoma-associated symptom burden were sustained through up to 52 weeks of treatment with relugolix combination therapy in women with uterine leiomyomas. No new safety concerns were identified, and BMD was maintained. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov , NCT03049735; NCT03103087; NCT03412890. FUNDING SOURCE: Myovant Sciences GmbH.
引用
- Al-Hendy A, Lukes AS, Poindexter AN, et al. Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas. Obstet Gynecol. 2022. PMID: 36357960. doi:10.1097/AOG.0000000000004988
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。